Pharmacotherapy of anaemia in cancer patients

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 12, 2001, Pages 1949-1961

  Mercadante, S ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Anaemia; Blood transfusion; Cancer; Erythropoietin ; Haemoglobin

Indexed keywords

CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOKINE; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IFOSFAMIDE; IRON; LEUPRORELIN; PLATINUM DERIVATIVE; PREDNISONE;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROPOIESIS; HEALTH HAZARD; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HORMONE SYNTHESIS; HUMAN; INCIDENCE; QUALITY OF LIFE; REVIEW; STEM CELL;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS;

EID: 0035203566     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.12.1949     Document Type: Review

References (91)

1. The hematologic support of the cancer patient
2. Chemotherapy-induced anemia in adults: Incidence and treatment
3. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
4. Proinflammatory cytokines lowering erythropoietin production
5. An epidemiological review of red cell transfusions in cancer chemotherapy
6. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
7. A retrospective review of blood transfusions in cancer patients
8. Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey
9. Is there an optimal hemoglobin level?
10. Special report: Transfusion risks
11. Transfusion-induced immunologic unresponsiveness
12. Effect of blood transfusion on disease-free interval after rectal cancer surgery
13. Association between transfusion of stored blood and infective bacterial complications after resection for colorectal cancer
14. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: A Mayo/North Central Cancer Treatment Group study
15. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma
16. Perioperative blood transfusion in hepatocellular carcinomas: Influence of immunologic profile and recurrence free survival
17. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or function?
18. B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy
19. Alternatives to stem cell renewal from a development viewpoint
20. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2
21. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia
22. A survival model of erythropoietin action
23. Decreased erythropoietin response in patients with anemia due to cancer
24. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy
25. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production
26. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy
27. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical studies
28. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
29. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia
30. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, Phase III study)
31. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy
32. Epoetin alpha prevents anemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
33. Randomized Phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
34. Economic outcomes associated with the use of hematopoietic growth factors
35. Recombinant human erythropoietin therapy for anemia cancer patients on combination chemotherapy
36. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
37. A multicenter study of recombinant human erythropoietin in the management of anemia in cancer patients receiving chemotherapy
38. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
39. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin an anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy
40. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomised, double-blind, placebo-controlled trial
41. Impact of therapy with epoietin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
42. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
43. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration
44. Increase of bone marrow cellularity during erythropoietin treatment in myeloma
45. Use of erythropoietin in oncology
46. The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma
47. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomised, Phase III study)
48. Anemia of cancer patients. Patient selection and patient stratification for epoetin treatment
49. Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma
50. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience
51. Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors
52. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience
53. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
54. Epoetin alfa in radiotherapy
55. Blood hemoglobin level may affect radiosensitivity - Preliminary results on acutely reacting normal tissues
56. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer
57. Autologous and heterologous blood transfusion in head and neck cancer surgery
58. Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients
59. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: Flow cytometry of Th1/Th2 cells in peripheral blood
60. A tailored perioperative blood transfusion might avoid undue recurrence in gastric carcinoma patients
61. The impact of intraoperative autologous blood transfusion during Type III radical hysterectomy for early-stage cervical cancer
62. Usefulness of autologous blood transfusion for avoiding allogenic transfusion and infectious complications after esophageal cancer resection
63. The role of human recombinant erythropoietin in oncologic surgery
64. Autologous blood transfusion in patients with hepatocellular carcinoma undergoing hepatectomy
65. Blood use in lung resection for carcinoma: Perioperative elective anemia does not compromise the early outcome
66. The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy
67. Effect of recombinant human erythropoietin in anaemia after gastrectomy: A pilot study
68. Erythropoiesis after therapy with recombinant human erythropoietin: A dose-response study in anemic cancer surgery patients
69. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomised study
70. Randomized multicentre trial of the influence of recombinant human erythopoietin on intraoperative and postoperative transfusion need in anaemic patints undergoing right hemicolectomy for carcinoma
71. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyoma
72. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trial
73. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens
74. Recombinant human erythropoietin in the anemia associated with multiple lyeloma or non-Hodgkin's lymphoma: A dose finding and identification of predictors of response
75. Prediction of response to erythropoietin treatment in chronic anemia of cancer
76. rhEPO treatment for the anemia of multiple myeloma and non-Hodgkin's lymphoma
77. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia in cancer
78. Prevention of chemotherapy-related anemia by recombinant human erythopoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support
79. Red blood cell precursor mass as an independent determinant of serum erythropoietin level
80. Erythropoietin therapy
81. rhEPO in the treatment of anemia associated with malignancy
82. Cinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
83. The effect of Epoetin alfa on quality of life in anemic cancer patients
84. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy
85. Cost of outpatient blood transfusion in cancer patients
86. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy
87. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis
88. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
89. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy
90. Anemia in cancer: Pathophysiology and treatment
91. Novel erythropoiesis stimulating protein (NESP) for the treatment of anemia of chronic disease associated with cancer